DOJ Intensifies Enforcement Against Telehealth Controlled Substance Prescribing Violations
The Department of Justice (DOJ) has significantly ramped up its enforcement efforts against telehealth companies and individual practitioners engaged in illegal prescribing and distribution of controlled substances. This aggressive stance underscores a commitment to combating the opioid crisis and preventing the diversion of prescription medications through digital healthcare platforms. Recent actions highlight a clear message: telehealth, while offering convenience and access, is not exempt from the stringent regulations governing controlled substances.
The Legal Framework: Ryan Haight Act and DEA Regulations
At the core of these prosecutions is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. This federal law generally requires at least one in-person medical evaluation before a practitioner can issue a prescription for a controlled substance via the internet. While the COVID-19 Public Health Emergency (PHE) waivers temporarily allowed for prescribing controlled substances via telehealth without an initial in-person visit, these waivers have largely expired, and the DEA has been working on permanent rules. The DOJ's enforcement actions often target conduct that occurred outside the scope of these waivers or involved clear violations of medical standards and federal law.
The Drug Enforcement Administration (DEA), under the authority of the DOJ, is responsible for enforcing the controlled substances laws and regulations. Their regulations, particularly those related to the dispensing of controlled substances, are critical. The DOJ's focus is on ensuring that prescriptions are issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. When this standard is not met, especially in a high-volume telehealth setting, it triggers severe scrutiny.
Common Violations Targeted by the DOJ
DOJ investigations and prosecutions frequently uncover several recurring patterns of illegal activity:
- Prescribing without a Legitimate Medical Purpose: This is perhaps the most common charge. It involves providers issuing prescriptions for controlled substances without a proper patient evaluation, based solely on online questionnaires, or without establishing a genuine patient-provider relationship. The DOJ views such actions as facilitating drug diversion rather than providing legitimate medical care.
- Lack of Prior In-Person Medical Evaluation: Despite the PHE waivers, many schemes pre-dated or operated outside the scope of these temporary flexibilities. The Ryan Haight Act's general requirement for an initial in-person exam remains a key enforcement tool.
- High-Volume, Rapid Prescribing: Companies or individuals who rapidly prescribe large quantities of controlled substances to numerous patients, often without adequate follow-up or monitoring, draw significant attention. This pattern often indicates a profit-driven motive over patient safety.
- Fraudulent Billing and Kickbacks: Many cases involve telehealth companies billing federal healthcare programs (like Medicare and Medicaid) for services that were not legitimately rendered or for prescriptions that were medically unnecessary. Kickback schemes, where providers receive payments for referring patients or prescribing specific medications, are also a major focus.
- Misrepresentation and Deception: Some cases involve companies making false claims about the legitimacy of their services, the qualifications of their providers, or the medical necessity of their prescriptions.
Recent Enforcement Trends and Examples
The DOJ has made it clear that combating healthcare fraud, including that committed via telehealth, is a top priority. Recent press releases from the DOJ and DEA consistently highlight large-scale takedowns involving multiple defendants across various states.
For instance, the DOJ has announced coordinated enforcement actions targeting hundreds of individuals, including doctors, nurses, and pharmacists, for their roles in schemes involving fraudulent telehealth prescriptions for controlled substances, often resulting in hundreds of millions of dollars in false billings. These actions frequently involve the illegal prescribing of opioids, stimulants (like Adderall), and benzodiazepines.
One notable trend involves schemes where telehealth companies allegedly exploited the relaxed telehealth rules during the PHE to prescribe controlled substances without proper medical evaluation. These cases often reveal that providers were pressured to prescribe, or that the business model incentivized high-volume prescribing without regard for medical necessity.
What This Means For Your Practice
The DOJ's aggressive stance has profound implications for all healthcare businesses utilizing telehealth, regardless of specialty. The message is clear: compliance with federal and state controlled substance laws is non-negotiable, and the convenience of telehealth does not diminish regulatory obligations.
For Telehealth Platforms and Providers:
- Robust Compliance Programs: Implement and enforce a comprehensive compliance program that specifically addresses controlled substance prescribing via telehealth. This includes clear policies, procedures, and regular training for all staff and affiliated providers.
- Legitimate Patient-Provider Relationship: Ensure that a legitimate patient-provider relationship is established before prescribing controlled substances. This typically involves a thorough medical history, physical examination (or an appropriate telehealth equivalent where permissible), and a documented assessment of medical necessity.
- Adherence to Ryan Haight Act: Understand and strictly adhere to the Ryan Haight Act's requirements, especially concerning the initial in-person examination for controlled substances. Stay informed about the DEA's evolving permanent telehealth rules.
- Documentation is Key: Maintain meticulous medical records justifying every prescription, including the rationale for the chosen medication, dosage, and duration. Document all patient interactions, assessments, and follow-ups.
- Monitor Prescribing Patterns: Implement systems to monitor provider prescribing patterns for controlled substances to identify and address outliers or potentially problematic behavior.
For Medspas, Dental Practices, and Chiropractic Offices:
Even if controlled substances are not a primary focus, any engagement with telehealth for prescribing, or partnering with telehealth providers, carries risk:
- Due Diligence in Partnerships: If partnering with third-party telehealth platforms, conduct thorough due diligence to ensure their compliance with controlled substance regulations. Your practice could be implicated if you are seen as facilitating illegal activity.
- Scope of Practice: Ensure that any telehealth prescribing aligns with the scope of practice for your licensed professionals and adheres to state-specific regulations for telehealth and controlled substances.
- Awareness of Red Flags: Educate staff on red flags for potential drug diversion or fraudulent prescribing, such as patients seeking specific controlled substances, paying in cash, or exhibiting drug-seeking behavior.
Conclusion
The Department of Justice's sustained and intensified focus on illegal controlled substance prescribing via telehealth is a critical regulatory development. Healthcare businesses must prioritize robust compliance, ethical prescribing practices, and a clear understanding of federal and state laws, particularly the Ryan Haight Act and DEA regulations. Proactive measures to ensure legitimacy and patient safety are paramount to mitigate legal and financial risks in this evolving regulatory landscape.